Ambry Genetics Unveils Precision Diagnostics Network

Konica Minolta Precision Medicine Inc., the Japan-based parent company of Aliso Viejo’s Ambry Genetics Corp., recently announced a five-year collaboration with Amazon to support the advancement and rollout of its precision diagnostics network. The deal includes an undisclosed financial investment from Amazon, the companies said.
 
Current data processing and computational systems cannot support the amount of information generated by molecular imaging and diagnostics, which limits the advancement of precision medicine. For example, studying just one human genome requires about 3 billion units of DNA across 23,000 genes, the company said.
 
KMPM aims to address this barrier with its diagnostics network, called Lattice, which is being distributed to its lab partners around the world to combine diagnostics, imaging and informatics in one platform.
 
Lattice runs on Amazon Web Services cloud and uses its storage, compute, database and analytics offerings to combine and aggregate genomics, pathology and radiology data.

“Ambry will be contributing de-identified genomic data to the platform to provide insights into various disease states including oncology and neurology,” Chief Executive Aaron Elliott said. “This information provided by Ambry will help us drive innovation by developing more informative diagnostic tests. In addition, the platform will provide clinicians and pharmaceutical companies the data insights they need to make better healthcare decisions and targeted therapies.”